Beyond Symptoms: Gain Unprecedented Insight into Your Cardiac Condition’s Hereditary Risks

A deeper exploration of the cutting-edge science behind the Ayass Bioscience Cardiac Genetic Analysis

Understanding the Science

Understand Your Genetic Risk for Heart Disease — With Precision. Comprehensive analysis of 174 genes linked to 17 cardiovascular disorders.

If you’re navigating heart-related health challenges or have a family history of cardiac conditions, genetic insights can be a powerful tool. Our advanced genetic test is designed to uncover the inherited causes of cardiovascular disease—offering far more than a routine screening.

This comprehensive panel analyzes 174 genes associated with 17 types of cardiovascular disorders, including cardiomyopathies, arrhythmias, high cholesterol and triglyceride levels, aortopathies, and more. Even if you’re not experiencing symptoms, this test can reveal hidden genetic risks that may impact your heart health down the line.

Using a simple cheek swab or small blood sample, our certified genetics lab at Ayass Bioscience in Dallas-Fort Worth performs an in-depth analysis that reaches beyond standard methods. We identify genetic variants traditional tests often miss—helping you and your doctor make informed decisions about prevention, monitoring, and care.

The Cardiac Genetic Enigma: Why Deeper Genetic Understanding is Key

Heart Disease Begins at the Molecular Level. So Should Your Testing. Cardiac conditions are often deeply rooted in genetics.

While standard diagnostic tools offer only a limited view, a more complete understanding begins with uncovering the inherited variations that influence how your heart develops, functions, and regulates itself.

Our advanced genetic panel is built to do just that. It takes a deeper dive into your DNA to examine:

Our panel examines 174 genes critical to cardiovascular health — including those involved in cardiomyopathies, heart rhythm disorders (arrhythmias), cholesterol and lipid regulation, and aortic conditions (aortopathies). This broad yet focused analysis helps uncover inherited risks that often remain undetected by conventional testing.

We go beyond surface-level screening by identifying not just well-known mutations, but also likely pathogenic variants and variants of uncertain significance (VUS). This detailed genetic profiling allows for a more precise understanding of your potential risk, even in the absence of symptoms.

We map how each identified variant may influence your cardiovascular health and risk profile, helping to clarify what these findings could mean for you. This insight supports more informed decisions around prevention, monitoring, and treatment strategies.

Advanced data integration delivers unmatched clarity.
Our AI-driven analysis brings together complex genetic data to provide a level of detail and insight that represents the forefront of modern cardiovascular genomics.

What Sets Us Apart: Intelligent Integration Through AI.

At the core of our approach is the Proprietary Agentic AI Platform, developed by Ayass Bioscience. This advanced system doesn’t just process genetic data — it interprets complex patterns across multiple genes to deliver insights with clarity and precision. By combining cutting-edge analytics with expert interpretation, our platform provides a depth of understanding that goes far beyond traditional genetic testing.

Explore Key Cardiovascular Conditions

Our test screens for genetic variants linked to key cardiovascular conditions.
Click on any condition below to explore how genetics may play a role and what our analysis can uncover:

Cardiomyopathies: Genetic Conditions That Weaken the Heart Muscle
Cardiomyopathies affect the heart’s ability to pump blood efficiently. Many forms are inherited, caused by variants in genes responsible for the structure and function of heart muscle proteins.
Our analysis focuses on identifying genetic variants associated with:

Hypertrophic Cardiomyopathy (HCM)

Genes: MYH7, MYBPC3, TNNT2, TNNI3, TPM1, ACTC1, MYL2, MYL3

Clinical Impact:
The genes analyzed in this panel encode proteins that form the cardiac sarcomere—the essential contractile unit of heart muscle. Pathogenic variants can lead to abnormal thickening of the heart muscle, increasing the risk of arrhythmias and, in some cases, sudden cardiac death.

Dilated Cardiomyopathy (DCM)

Genes: TTN, LMNA, MYH7, MYBPC3, TNNT2, SCN5A

Clinical Impact:
Variants in these genes can lead to dilation and weakening of the heart muscle, a condition that impairs the heart’s ability to pump blood effectively. This may result in heart failure and a higher risk of developing arrhythmias.

Genes: PKP2, DSP, DSG2, DSC2, JUP, TMEM43

Clinical Impact:
These desmosomal genes are essential for maintaining strong cell-to-cell connections within the heart muscle. Pathogenic variants can disrupt this structure, causing the right ventricle to be progressively replaced by fatty and fibrous tissue, which significantly increases the risk of life-threatening arrhythmias.

Restrictive Cardiomyopathy

Genes: TNNI3, TNNT2, MYH7, ACTC1

Clinical Impact:
Certain genetic variants can cause the heart muscle to become abnormally stiff, reducing its ability to fill properly with blood between beats. This can lead to heart failure symptoms and, in severe cases, may result in the need for heart transplantation.

Gene Protein Function Associated Condition
MYH7 Beta-myosin heavy chain, motor protein for muscle contraction HCM, DCM
MYBPC3 Myosin-binding protein C, regulates muscle contraction HCM, DCM
TTN Titin, giant protein providing elasticity to muscle DCM
PKP2 Plakophilin-2, cell adhesion protein ARVC

Inherited Arrhythmia Syndromes: Genetic Disruptions in the Heart’s Electrical System
These conditions affect the electrical signals that regulate your heartbeat and can lead to irregular, potentially life-threatening rhythms. Many inherited arrhythmias are linked to genetic variants in ion channel genes, which govern how electrical currents flow through heart cells.
Our analysis focuses on identifying variants associated with:

Long QT Syndrome (LQTS)

Genes: KCNQ1, KCNH2, SCN5A, KCNE1, KCNE2, KCNJ2

Clinical Impact:
Genetic variants in potassium and sodium channel genes can disrupt the heart’s electrical signaling, leading to prolongation of the QT interval on an ECG. This increases the risk of developing a dangerous arrhythmia called torsades de pointes, which can lead to sudden cardiac death if not properly managed.

Brugada Syndrome

Genes: SCN5A, GPD1L, CACNA1C, CACNB2, SCN1B

Clinical Impact:
Variants—primarily in sodium channel genes—are associated with distinctive ECG patterns and a heightened risk of ventricular fibrillation, a life-threatening arrhythmia. These events often occur during sleep or in response to fever, making early detection and risk management critical.

Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)

Genes: RYR2, CASQ2, TRDN, CALM1, CALM2

Clinical Impact:
Genetic variants affecting calcium handling in heart cells can lead to severe arrhythmias triggered by physical activity or emotional stress. These conditions often present in children and young adults and may cause fainting, seizures, or sudden cardiac death if left undiagnosed.

Short QT Syndrome

Genes: KCNH2, KCNQ1, KCNJ2

Clinical Impact:
Gain-of-function variants in potassium channel genes can cause the QT interval to become abnormally short, disrupting the heart’s normal rhythm. This increases the risk of developing atrial fibrillation and may lead to sudden cardiac death, especially in younger individuals or those without other symptoms.

Gene Ion Channel Type Associated Syndrome
KCNQ1 Potassium channel (IKs current) LQTS1, SQTS2
KCNH2 Potassium channel (IKr current) LQTS2, SQTS1
SCN5A Sodium channel (INa current) LQTS3, Brugada, DCM
RYR2 Calcium release channel CPVT1

Inherited Lipid Disorders: Genetic Risks for Early Cardiovascular Disease
These conditions affect how your body processes cholesterol and other blood lipids, often leading to elevated levels from a young age. If left undetected, they can significantly increase the risk of early-onset heart disease.
Genetic testing allows for early identification and targeted intervention.
Our analysis examines variants associated with:

Familial Hypercholesterolemia (FH)

Genes: LDLR, APOB, PCSK9, LDLRAP1

Clinical Impact:
Genetic variants in these genes can impair the body’s ability to clear LDL (“bad”) cholesterol, resulting in severely elevated cholesterol levels from an early age. This dramatically increases the risk of premature coronary artery disease. With early diagnosis, intervention—often with statins—can be life-saving.

Familial Hypertriglyceridemia

Genes: LPL, APOC2, APOA5, GPIHBP1, LMF1

Clinical Impact:
Variants that disrupt triglyceride metabolism can lead to severe hypertriglyceridemia, significantly raising the risk of acute pancreatitis and contributing to cardiovascular disease. Early detection can guide dietary changes and medical therapies to reduce these risks.

Sitosterolemia

Genes: ABCG5, ABCG8

Clinical Impact:
Genetic variants in sterol transporter genes can lead to the buildup of plant sterols in the body, resulting in premature atherosclerosis and the development of distinctive xanthomas (fatty skin deposits). Early diagnosis enables tailored dietary and therapeutic interventions to manage these risks.

Tangier Disease

Genes: ABCA1

Clinical Impact:
Variants in the cholesterol efflux transporter gene can result in markedly low HDL (“good”) cholesterol levels, increasing the risk of cardiovascular disease. A hallmark physical sign of this condition is the presence of orange-colored tonsils. Early detection is key for risk management and family screening.

Gene Protein Function Lipid Effect
LDLR LDL receptor for cholesterol uptake Elevated LDL cholesterol
PCSK9 Regulates LDL receptor degradation Elevated or reduced LDL cholesterol
LPL Lipoprotein lipase for triglyceride hydrolysis Elevated triglycerides
ABCA1 Cholesterol efflux transporter Severely low HDL cholesterol

Inherited Aortopathies: Genetic Risks That Weaken the Body’s Main Artery
These conditions impact the structure and stability of the aorta, the body’s largest artery. If left undetected, they can lead to aortic dilation, aneurysms, and potentially fatal dissections.
Genetic testing allows for early identification, enabling proactive monitoring and intervention before serious complications arise.
Our analysis examines variants associated with:

Marfan Syndrome

Genes: FBN1

Clinical Impact:
Variants in the fibrillin-1 (FBN1) gene disrupt connective tissue integrity throughout the body. This often leads to aortic root dilation and a significantly increased risk of aortic dissection. Additional features may include skeletal abnormalities and ocular conditions, making early genetic diagnosis critical for comprehensive care.

Loeys-Dietz Syndrome

Genes: TGFBR1, TGFBR2, SMAD3, TGFB2, TGFB3

Clinical Impact:
Variants in genes involved in the TGF-β signaling pathway can lead to rapid and aggressive aortic dilation, often with a high risk of dissection even at smaller aortic diameters. These cases demand intensive monitoring and often call for earlier surgical intervention than typical aortic conditions.

Ehlers-Danlos Syndrome (Vascular Type)

Genes: COL3A1

Clinical Impact:
Variants in the type III collagen gene (COL3A1) result in fragile blood vessels and internal organs, significantly increasing the risk of arterial rupture and aortic dissection, often at a young age. Early diagnosis is essential for tailored medical management and lifestyle precautions to reduce life-threatening complications.

Bicuspid Aortic Valve Disease

Genes: NOTCH1, GATA5, NKX2-5

Clinical Impact:
Genetic variants that influence cardiac development can lead to the formation of a bicuspid aortic valve, a condition where the valve has two leaflets instead of three. This is frequently associated with ascending aortic dilation and an elevated risk of aortic complications, including aneurysm and dissection.

Condition Primary Gene Aortic Risk
Marfan Syndrome FBN1 Aortic root dilation, dissection risk
Loeys-Dietz Syndrome TGFBR1/2 Aggressive dilation, early dissection
Vascular EDS COL3A1 Arterial fragility, rupture risk
Bicuspid Aortic Valve NOTCH1 Ascending aortic dilation

Genetic Analysis: Revealing Your Cardiac Predispositions

Understanding Genetic Predisposition Testing

Think of your DNA as your body’s instruction manual—our test finds the pages that matter most to your heart.
By analyzing variations in key genes linked to cardiovascular health, our test helps identify inherited risk factors that could predispose you to serious cardiac conditions, often before symptoms appear.

Many heart conditions have a strong genetic foundation.
Identifying these genetic risk factors early empowers you to take proactive steps—whether it’s preventing disease, delaying its onset, or managing an existing condition more effectively. Knowledge of your genetic profile can be a powerful tool in protecting your long-term heart health.

Genetic testing reveals risks before symptoms appear.
By uncovering potential genetic predispositions early, we gain powerful insight into your likelihood of developing certain cardiac conditions—often before any clinical signs emerge. This foresight enables more personalized and preventive care.

Variant Classification

Our analysis classifies genetic variants according to established guidelines:

PATHOGENIC:
Variants that are known to cause disease.

LIKELY PATHOGENIC:
Variants with strong evidence suggesting they cause disease.

VARIANT OF UNCERTAIN SIGNIFICANCE (VUS):
Variants where the clinical impact is currently unclear.

LIKELY BENIGN:
Variants unlikely to be associated with disease.

BENIGN:
Variants that are not associated with disease.

Frequently Asked Questions

What exactly does this test look for? Does it cover all types of heart conditions?

This test is designed to uncover genetic variants linked to inherited heart conditions.
It analyzes 174 genes connected to 17 types of cardiovascular disorders, including cardiomyopathies, arrhythmia syndromes, familial hypercholesterolemia, hypertriglyceridemia, aortopathies, and more. While the panel covers a broad range of genetic heart conditions, not all cardiac issues are genetic in origin.

This test is especially valuable for those who:

  • Have a family history of heart disease

  • Experienced unexplained cardiac symptoms at a young age

  • Want to understand their genetic risk before symptoms appear

How is this genetic heart test different from the standard tests my doctor might recommend?

Traditional heart tests check how your heart is working today — our test looks at your future risk.
Tests like ECGs, echocardiograms, stress tests, and blood work show how your heart is functioning right now. Our cardiac genetic test takes a different approach: it identifies inherited genetic variants that may raise your risk of developing heart conditions — often before any symptoms appear.

We analyze 174 genes across 17 inherited cardiac conditions in a single, comprehensive panel — far more than most clinical genetic tests. Our Agentic AI platform goes beyond a basic positive/negative result by interpreting your data through the lens of the latest research, offering personalized insights and risk assessments to guide prevention and care.

Can you explain “genetic predisposition analysis” in plain language?

Genetic predisposition analysis looks for variations in your DNA that may raise your risk for heart conditions.
Think of your DNA as your body’s instruction manual. Sometimes, small changes in those instructions — called genetic variants — can increase your chance of developing certain cardiac disorders over time.

Our test analyzes 174 genes linked to heart health, identifying any variants that could impact you. These are then classified using well-established scientific guidelines, helping your care team understand whether a variant is likely to affect your heart function or disease risk.

You mentioned “Agentic AI” — what is it and how does it help?

Agentic AI is our advanced artificial intelligence platform that helps make sense of complex genetic data.
In this test, specialized AI “agents” analyze your genetic variants, looking for important patterns — such as which genes may increase your heart risk, how those genes interact within key biological pathways, and how everything ties back to known mechanisms of cardiac disease.

This smart, integrated approach allows us to provide deeper, more personalized insights than traditional genetic reporting.

Is the sample collection process uncomfortable or hard to do?

Not at all — sample collection is quick, easy, and completely painless.
Our test uses a simple at-home cheek swab that takes less than 2 minutes to complete. The kit includes everything you need:

  • A medical-grade foam-tipped swab

  • A sterile collection tube

  • Prepaid return packaging

All you need to do is gently swab the inside of your cheek for about 30 seconds, place the swab into the tube, and send it back — no needles, no blood, no discomfort.
If preferred, the test can also be done using a small blood sample collected in a clinical setting.

How long does it take to get my results after sending in the sample?

Once your sample arrives at our lab, your results are typically ready in 3–4 weeks.
After your sample reaches Ayass Bioscience, it’s processed through our advanced Transcriptome Data Center and analyzed using our proprietary Agentic AI platform. This in-depth process takes time to ensure accuracy and detail, but you’ll typically receive your full report within 3 to 4 weeks.
We’ll keep you updated every step of the way.

What details will be included in my genetic report?

Your report offers a detailed view of your genetic heart health — not just a yes/no answer.
You’ll receive personalized insights into any genetic variants that may impact your cardiac health, along with information on the biological pathways those variants affect. The report also explains how these patterns may relate to the mechanisms behind inherited heart conditions.
It’s a comprehensive genetic snapshot, designed to inform long-term prevention, monitoring, and care — not just a diagnosis checklist.

Will this test tell me exactly what heart condition I have or which treatment I need?

This test is designed to provide deep insights into the genetic factors potentially contributing to your cardiac health risks. It does not diagnose specific cardiac conditions or recommend specific treatments. Its purpose is to offer valuable information that you and your healthcare provider can use to better understand your genetic predispositions and discuss potential personalized prevention strategies.

How can I use the results from this test to guide my care?

Your results can guide more personalized care with your doctor or cardiologist.
The insights in your report offer valuable context about your unique genetic risk factors. This information can support deeper conversations with your healthcare provider, helping them tailor follow-up tests, prevention strategies, or treatment plans that align with your individual genetic profile.

Which genes are included in this test?

ur panel analyzes 174 carefully selected genes linked to 17 inherited heart conditions.
These include genes involved in:

  • Heart structure (e.g., MYH7, MYBPC3, TTN – linked to cardiomyopathies)

  • Electrical signaling (e.g., KCNQ1, KCNH2, SCN5A – associated with arrhythmias)

  • Cholesterol regulation (e.g., LDLR, APOB, PCSK9 – tied to hypercholesterolemia)

  • Connective tissue integrity (e.g., FBN1, TGFBR1, TGFBR2 – involved in aortopathies)

Each gene is included based on strong scientific evidence connecting it to inherited cardiovascular disease.

How reliable is this genetic analysis?

We use Next Generation Sequencing (NGS) with >99.9% analytical accuracy.
Our testing is performed with high-depth coverage (minimum 30x) across all targeted regions to ensure reliable and reproducible variant detection. We follow strict quality control standards to maintain clinical-grade accuracy.

While our ability to detect genetic variants is extremely precise, the interpretation of their clinical impact is an evolving field. That’s where our Agentic AI platform adds unique value — continuously integrating the latest research to provide the most up-to-date variant classifications possible.

What types of genetic variants can be detected?

Our test detects several types of genetic variants that can impact heart health, including:

  • Single nucleotide variants (SNVs): Small changes to a single DNA letter

  • Small insertions and deletions (indels): Tiny added or missing DNA segments

  • Copy number variations (CNVs): Larger segments of DNA that are duplicated or deleted

We focus on the coding regions (exons) and nearby splice sites of all 174 genes — the areas where most disease-causing variants are found. However, please note that very large genomic rearrangements and variants in deep intronic (non-coding) regions may not be detected.

How do you determine whether a variant is harmful or not?

We classify genetic variants using established guidelines from the American College of Medical Genetics and Genomics (ACMG).
This involves evaluating multiple factors, including:

  • Whether the variant has been previously linked to cardiac disease

  • How common or rare it is in healthy individuals

  • Its impact on protein structure and function

  • Results from functional laboratory studies, if available

  • How well the affected DNA region is conserved across species (a sign of importance)

Our Agentic AI platform enhances this process by bringing together all these data points and continuously comparing your results with the latest scientific research, offering a more precise and dynamic classification than static algorithms alone.

What makes your “Proprietary Agentic AI Platform” uniquely effective for cardiac genetics?

The Agentic AI Platform was purpose-built to interpret complex genetic data related to heart health.
Developed by Ayass Bioscience’s F420.ai, this proprietary platform is specifically trained to analyze genetic variants within the context of cardiovascular disease. Unlike general AI tools, Agentic AI focuses on the interconnected nature of cardiac-related genes and biological pathways.

It doesn’t just flag individual variants — it integrates patterns across your entire genetic profile, delivering a holistic, insight-rich view that goes far beyond isolated data points.

What’s the connection between Ayass Bioscience and F420.ai?

F420.ai is the in-house innovation arm of Ayass Bioscience.
This means our Agentic AI platform is developed and operated entirely within Ayass Bioscience, ensuring a seamless connection between lab testing and advanced data analysis at our Transcriptome Data Center.

By keeping everything under one roof, we maintain tight quality control, allow for continuous refinement, and ensure that our tools are uniquely focused on complex conditions like inherited cardiac disorders.

How does this analysis differ from a standard genetic (DNA) test for heart conditions?

Most standard genetic tests offer a narrow view — ours goes much deeper.
Traditional DNA tests typically screen for a small set of known mutations tied to certain heart conditions. In contrast, our analysis covers 174 genes associated with 17 different inherited cardiovascular disorders, offering a far more comprehensive picture of your genetic heart health.

This broader approach provides a detailed snapshot of your inherited cardiac risk across a wide range of potential conditions — not just a select few.

What role does the Ayass Bioscience Transcriptome Data Center play in this process?

The Ayass Bioscience Transcriptome Data Center is where your sample becomes meaningful data.
This state-of-the-art molecular lab is where we perform all physical processing — from DNA extraction of your buccal swab to high-throughput sequencing that generates your raw genetic data.

Once complete, your data is transferred to our F420.ai Agentic AI Platform for in-depth analysis, turning raw sequences into actionable insights about your heart health.

Can this test identify all genetic causes of heart disease?

While highly comprehensive, no genetic test can detect every possible cause of heart disease.
Our test analyzes 174 genes linked to 17 inherited cardiac conditions, offering broad and in-depth coverage. However, cardiac genetics is a rapidly evolving field, and new disease-associated genes continue to be discovered.

Some heart conditions also involve complex genetic interactions or gene-environment factors that current testing methods may not fully capture. To stay ahead, we regularly update our gene panel based on the latest research, ensuring our analysis reflects the most current understanding in cardiac genetics.

Why does this cardiac genetic test cost $799? What’s included in the price?

The cost reflects the depth, accuracy, and innovation built into this advanced genetic test.
Unlike basic genetic tests, this is a comprehensive analysis designed to uncover hidden inherited cardiac risks. The $799 price includes:

  • Full Genetic Sequencing of 174 genes linked to 17 cardiovascular disorders

  • Complex Laboratory Processing at our Ayass Bioscience facility

  • Proprietary Agentic AI Analysis via the F420.ai platform, offering deep interpretation of genetic interactions and pathways

  • Detailed, Personalized Reporting that translates complex findings into clear, actionable insights

This is not a surface-level screen — it’s a clinical-grade genetic investigation into your unique cardiac risk profile.

How does the 10% discount work when ordering more than one kit?

You’ll receive 10% off each additional kit after the first — perfect for family use.
When you order more than one Cardiac Genetic Insight Kit, every additional kit is discounted to $719 (10% off the base price). This is ideal for family members who may share similar inherited risks.

The discount can be applied when ordering multiple kits at once, or you can contact us directly to apply it to future orders from the same household.

What’s included in the cardiac genetic test kit?

Your kit includes everything you need for easy, at-home sample collection.
Each Cardiac Genetic Insight Kit comes with:

  • Sterile buccal (cheek) swabs

  • Step-by-step instructions

  • A sterile collection tube

  • Prepaid return packaging and shipping label

There’s nothing else to purchase — simply follow the instructions and send your sample back using the materials provided.

Do I need to pay for shipping—either to receive the kit or return my sample?

No shipping costs — it’s completely free, both ways.
We cover all shipping expenses. Your kit includes a prepaid return label, so you can send your sample back to our lab at no cost to you. There are no hidden fees for shipping or processing.

Which shipping service do you use, and is there a reason for that choice?

We ship via FedEx to ensure speed, reliability, and specimen integrity.
We use FedEx because of its proven track record in handling biological samples with care and temperature sensitivity. This helps ensure that your specimen arrives at our lab quickly and in optimal condition for accurate analysis.

Is this test available for customers outside the United States?

At this time, our cardiac genetic testing is available only within the United States.
If you’re located outside the U.S., please check our website or contact our customer support team for the most current information on international availability and future expansion.

A Test You Can Trust

Genetic Testing - Hereditary Cancer

Comprehensive analysis of 174 genes linked to 17 cardiovascular conditions

Order Cardiac Genetic Testing Kit – SPECIAL OFFER!

Our Process

Order your kit online and collect your DNA sample using an easy, non-invasive buccal (cheek) swab. Clear, step-by-step instructions are included to guide you through the process.

Return your sample using the prepaid FedEx packaging included in your kit. Samples are shipped directly to our Ayass Bioscience laboratory in Dallas–Fort Worth. No extra shipping costs.

At the lab, we extract and sequence your DNA, focusing on 174 genes known to be associated with 17 inherited cardiac conditions.

Your genetic data is analyzed through a specialized bioinformatics pipeline developed by F420.ai, an Ayass Bioscience company. This multi-step process includes:

  • Data Processing & Quality Control: Ensures high-quality, accurate sequencing data.

  • Variant Calling & Annotation: Identifies genetic variants and annotates them using curated clinical and population databases.

  • Clinical Association Mapping: Links variants to specific cardiac conditions and categorizes them by clinical significance using established guidelines (e.g., ACMG).

  • Risk Insight Reporting: Compiles a clear, in-depth report outlining identified variants, associated conditions (if any), and inherited cardiac risk implications.

You’ll receive a detailed, easy-to-understand report highlighting:

  • Key genetic variants

  • Their potential clinical significance

  • Personalized insights to guide prevention, monitoring, or treatment strategies

View your results anytime through our secure patient portal. Your genetic data remains a valuable asset — as new cardiac genetic discoveries emerge, your report can be re-evaluated over time for continued relevance to your health.

The Ayass Bioscience Difference

Our test examines 174 genes associated with 17 inherited cardiovascular conditions — including cardiomyopathies, arrhythmias, hypercholesterolemia, aortopathies, and more — offering one of the most comprehensive cardiac genetic analyses available today.

Gain insights that would normally require multiple specialized tests costing thousands of dollars — now delivered in a single, integrated analysis designed to uncover your inherited risk across a broad spectrum of cardiac conditions.

Our exclusive Agentic AI platform, developed by Ayass Bioscience, functions like a virtual team of cardiovascular genetics experts — working together to interpret your data. This multi-agent system uncovers complex patterns and interactions across genes, delivering insights that go far beyond conventional analysis.

We go beyond one-size-fits-all care. Your genetic analysis provides actionable insights that can help you and your doctor develop targeted prevention and treatment plans — all tailored to your unique genetic risk profile.

Your genetic data isn’t just a one-time snapshot — it’s a long-term resource. As scientific discoveries evolve, your results can be re-evaluated over time, offering new insights that may guide your care for years to come.

What You’ll Receive

Professional testing kit with clear instructions

Prepaid FedEx shipping materials

Secure sample collection tubes

Comprehensive genetic analysis report

BE PROACTIVE – Know your genetic predisposition to various types of cardiac conditions (heart diseases) and TAKE ACTION BASED ON YOUR RESULTS

Lifestyle and diet aren’t the only factors of the health of your heart. Genetics play a major role in it. Take action today and get a better understanding of your heart health. Genetic testing identifies changes in your genes that could increase your risk for developing a serious, inherited form of heart disease, even if you are generally healthy and without personal or family history.

We are bridging science to clinical practice by implementing cutting edge technology to evaluate your hereditary cardiac conditions risk. We provide DNA sequencing for targeted panels, allowing us to focus on specific areas of interest at a reduced price and faster delivery time.

Our laboratory’s technology can accommodate samples collected by medical grade foam tipped buccal swab, making it a viable alternative to a trip to the phlebotomist and reducing the impact of blood-drawing on patients’ health.

Our Cardio Sequencing Panel focuses on identifying 17 inherited cardiac conditions

Our panel targets 174 genes with known associations to 17 inherited cardiac conditions including cardiomyopathy, arrhythmia, hypercholesterolemia, hypertriglyceridemia, aortopathy and more. This assay is performed using genomic DNA isolated from blood collected via capillary puncture or a swab.

The test is intended for predictive genetic testing to determine the chances that a healthy individual with or without a family history of cardiac conditions might develop heart disease.

It is also performed as a pre-symptomatic genetic testing in order to determine whether an individual with a family history of cardiac disease, but no current symptoms, has the gene alterations associated with heart disease. It is also intended for post-symptomatic genetic testing to identify the potential underlying cause of an existing cardiac disease.

ABCC9, ABCG5, ABCG8, ACTA1, ACTA2, ACTC1, ACTN2, AKAP9, ALMS1, ANK2, ANKRD1, APOA4, APOA5, APOB, APOC2, APOE, BAG3, BRAF, CACNA1C, CACNA2D1, CACNB2, CALM1, CALR3, CASQ2, CAV3, CBL, CBS, CETP, COL3A1, COL5A1, COL5A2, COX15, CREB3L3, CRELD1, CRYAB, CSRP3, CTF1, DES, DMD, DNAJC19, DOLK, DPP6, DSC2, DSG2, DSP, DTNA, EFEMP2, ELN, EMD, EYA4, FBN1, FBN2, FHL1, FHL2, FKRP, FKTN, FXN, GAA, GATAD1, GCKR, GJA5, GLA, GPD1L, GPIHBP1, HADHA, HCN4, HFE, HRAS, HSPB8, ILK, JAG1, JPH2, JUP, KCNA5, KCND3, KCNE1, KCNE2, KCNE3, KCNH2, KCNJ2, KCNJ5, KCNJ8, KCNQ1, KLF10, KRAS, LAMA2, LAMA4, LAMP2, LDB3, LDLR, LDLRAP1, LMF1, LMNA, LPL, LTBP2, MAP2K1, MAP2K2, MIB1, MURC (CAVIN4), MYBPC3, MYH11, MYH6, MYH7, MYL2, MYL3, MYLK, MYLK2, MYO6, MYOZ2, MYPN, NEXN, NKX2-5, NODAL, NOTCH1, NPPA, NRAS, PCSK9, PDLIM3, PKP2, PLN, PRDM16, PRKAG2, PRKAR1A, PTPN11, RAF1, RANGRF, RBM20, RYR1, RYR2, SALL4, SCN1B, SCN2B, SCN3B, SCN4B, SCN5A, SCO2, SDHA, SEPN1, SGCB, SGCD, SGCG, SHOC2, SLC25A4, SLC2A10, SMAD3, SMAD4, SNTA1, SOS1, SREBF2, TAZ, TBX20, TBX3, TBX5, TCAP, TGFB2, TGFB3, TGFBR1, TGFBR2, TMEM43, TMPO, TNNC1, TNNI3, TNNT2, TPM1, TRDN, TRIM63, TRPM4, TTN, TTR, TXNRD2, VCL, ZBTB17, ZHX3, ZIC3

Angina
Aortic Aneurysm
Atrial Fibrillation
Atherosclerosis
Cardiac Arrhythmia
Cardiac Arrhythmia Post Ablation
Cardiac Arrhythmia Post Pacemaker
Cardiomyopathy
Carditis
Carotid Artery Disease
Congenital Heart Conditions
Coronary Heart Disease
Coronary Heart Disease Post CABG (Bypass)
Coronary Heart Disease Post Stent Placement
Congestive Heart Failure
Heart Attack
Heart Block
Heart Failure
Heart Valve Disease
Hypercholesterolemia
Hypertensive Heart Disease
Inherited Heart Conditions
Peripheral Artery Disease
PVC’s Premature Ventricular Contraction
Stroke
Supraventricular Tachycardia (SVT)
Thromboembolic Disease
Venous Thrombosis

REQUISITION FORM AND SAMPLE REPORT

Why get tested?

ADVANCED KNOWLEDGE

This test might give you the advance knowledge that you might develop heart disease or that you might have a 50% increased risk of suffering a heart attack, which can help you make decisions that will limit the risk.
Mutations in genes can affect the way the heart cells communicate, the strength of the heart muscle, and affect the heart rhythm condition, resulting in fast, chaotic heartbeats. Identifying these genetic factors now plays an important role in the disease prognosis, therapy and, therefore, outcome.

MEDICATION RESPONSE

Up to 40% of people have gene variants that prevent their liver from activating medications, putting them at increased risk for a clot-caused heart attack. Our Pharmacogenetic Testing allows us to assess the likelihood that an individual will have a normal, reduced, or enhanced response to certain medications. This is very important because it dictates how a person responds to a treatment prior to actually receiving the treatment based on their genetics, improving efficacy and reducing adverse effects.

Implementing Genome-Driven Personalized Cardiology-in-Clinical-Practice

Cardiac Diseases and Related Genes

We strongly recommend that you seek genetic counseling to understand the limitations and possible consequences of this test.

ORDER FORMS • A LETTER FROM OUR PRESIDENT • SPECIMEN REQUIREMENTS • SPECIMEN COLLECTION INSTRUCTIONS • IF GENOMIC DNA IS ALREADY AVAILABLE • FAQ

All tests are performed at Ayass BioScience, LLC (DBA Ayass Laboratory, LLC), a CLIA-certified laboratory.
If you have any questions about Genetic Testing, Clinical Testing, Cytokine Testing, or Pharmacogenetic Testing at Ayass BioScience, LLC—or about Transcriptome Analysis (conducted at Ayass BioScience, LLC for research purposes only and not FDA-approved)—please call us at 972-668-6005 or fill out the contact form at the bottom of this page. We’ll be happy to answer your questions.